Summary
Bleecker Street Research has published a report targeting United Therapeutics (UTHR), a $13 billion pharmaceutical company that derives the majority of its revenue from the pulmonary hypertension drug Tyvaso. The firm argues that UTHR faces significant competitive pressure from Liquidia's (LQDA) newly launched competing product Yutrepia, which appears to be gaining market share faster than expected and could substantially erode UTHR's dominant market position.
Who is United Therapeutics?
United Therapeutics is a commercial-stage pharmaceutical company with a $13 billion market capitalization that focuses primarily on treatments for pulmonary arterial hypertension and related conditions. The company's flagship product, Tyvaso, is an inhaled form of treprostinil that was first approved by the FDA in 2009 for treating pulmonary arterial hypertension (PAH). In 2021, Tyvaso expanded its market by receiving approval for pulmonary hypertension associated with interstitial lung disease (PH-ILD), effectively granting the company a monopoly in this indication as no other approved treatments existed. As of Q1 2025, Tyvaso generates approximately $1.9 billion in annualized revenue and represents the majority of UTHR's total revenue, making the company heavily dependent on this single product's continued market dominance.
Key Points from Report
Legal Battles Finally Lost: The End of UTHR's Monopoly
- UTHR has been engaged in extensive litigation against Liquidia for five years, filing numerous patent infringement lawsuits and attempting various legal maneuvers to prevent Yutrepia's market entry, including arguing that delaying the competitor would serve the public good
- Despite UTHR's aggressive legal strategy, a series of courtroom defeats led to LQDA finally receiving FDA approval in May 2025, marking the first time since Tyvaso's 2009 launch that a directly competing product has entered the market
Rapid Market Penetration: Yutrepia's Swift Success
- Bleecker Street's July survey of 18 Tyvaso prescribers (including 11 top prescribers) revealed that Yutrepia had already captured an estimated 5% market share within just two months of its June launch
- Physicians surveyed indicated that Yutrepia adoption was broad-based, with new prescriptions split roughly evenly between Tyvaso switches and prostacyclin-naive patients, suggesting the drug is appealing to both existing and new patient populations
Superior Medical Profile: Why Doctors Prefer Yutrepia
- Yutrepia's PRINT technology creates particles roughly half the size of Tyvaso particles, which appears to improve tolerability and reduce discontinuations due to adverse events like persistent cough
- Patients in Yutrepia trials were able to escalate to doses that are multiples of the maximum dose achievable in Tyvaso DPI trials, while the ongoing Yutrepia ASCENT trial in PH-ILD patients showed no discontinuations at 8 weeks compared to Tyvaso DPI's 50%+ discontinuation rates in observational studies
Physician Enthusiasm: Market Share Projections
- Multiple top prescribers indicated they expect a 50/50 market share split between the two drugs longer-term, with some forecasting an 80/20 split in favor of Yutrepia, particularly in the PH-ILD indication where tolerability is crucial
- Several physicians stated they would likely make Yutrepia their preferred prescribing choice due to its better tolerability profile and ability to administer higher doses without treatment discontinuation
Financial Impact: Revenue Erosion Ahead
- Bleecker Street estimates that continued Yutrepia rollout at the observed pace will cause UTHR's Tyvaso sales to decline approximately 11% by 2026 versus 2024 levels, translating to a roughly 22% drop in 2026 earnings per share
- In their bear case scenario, the firm projects Yutrepia could capture 45% of the market by 2026, causing a 28% decline in Tyvaso revenues, 12% decline in total UTHR revenue, and 37% fall in earnings per share from 2024 to 2026
Pipeline Weakness: Limited Growth Options
- UTHR's potential expansion into idiopathic pulmonary fibrosis (IPF) with Tyvaso faces skepticism from physicians who believe IPF itself is unlikely to respond to Tyvaso treatment, as the drug may only address pulmonary hypertension symptoms rather than the underlying scarring process
- Even if Tyvaso receives IPF approval with orphan drug exclusivity, physicians indicated they would likely prescribe Yutrepia off-label for IPF patients since the underlying compound is identical, potentially limiting UTHR's exclusivity benefits
Future Competition: More Threats on the Horizon
- Insmed's treprostinil palmitil (TPIP) powder reported promising Phase 2 results in June and requires only once-daily administration compared to Tyvaso's 4 daily doses and Yutrepia's 3-5 daily doses, generating significant physician excitement for improved patient compliance
- Liquidia is also developing L606, a next-generation treprostinil suspension requiring only twice-daily administration, with plans to commence pivotal trials by end of 2025, while UTHR remains in preclinical stages for its once-daily equivalent as of April 2025
Activ8 Analysis
The competitive dynamics outlined in this report present a concerning picture for United Therapeutics' future market position. The rapid adoption of Yutrepia, evidenced by achieving 5% market share within two months despite years of legal obstacles, suggests that physician demand for alternatives to Tyvaso was substantial and pent-up. The clinical advantages highlighted by prescribers - improved tolerability, better dose escalation capabilities, and superior patient outcomes - indicate that Yutrepia may not simply be an alternative but potentially a superior therapeutic option.
The fact that UTHR executives and board members have sold $179 million in stock over the past 12 months, with the General Counsel alone accounting for $50 million, raises additional concerns about management's confidence in the company's ability to maintain its competitive position. The company's heavy dependence on Tyvaso revenue, combined with what appears to be a relatively weak pipeline and the emergence of multiple next-generation competitors with more convenient dosing regimens, suggests investors should carefully evaluate the sustainability of UTHR's current market dominance and revenue streams. The legal battles that have now been exhausted may have merely delayed the inevitable competitive pressures that were always going to emerge in this valuable therapeutic market.